Abbott said today that has signed an agreement to collaborate with Astellas Pharma Global Development in a phase III clinical trial for Astellas' investigational vaccine to prevent cytomegalovirus reactivation in transplant patients.

Under the agreement, researchers from the companies will use Abbott's RealTime CMV assay on the m2000 System to monitor patients for CMV viral load in order to assess the efficacy of the vaccine, called ASP0113, or TransVax.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.